Comparing the efficacy and safety of weekly somatrogon with daily somatropin in Asian children living with growth hormone deficiency: a plain language summary of publication

초록

Key takeaways center dot Children living with growth hormone deficiency (GHD) are usually treated with daily injections of a growth hormone called somatropin to help them grow normally. circle Somatrogon is a growth hormone treatment that only needs to be injected once a week. center dot A worldwide clinical study involving 224 children living with GHD found that weekly somatrogon injections were as effective (efficacy) and as safe as daily somatropin injections. Efficacy refers to how well a medicine works in a clinical study. center dot This analysis focused specifically on the 45 children of Asian ethnicity from this worldwide study. circle Asian children who received somatrogon grew as fast as those who received somatropin. circle Both treatment groups had IGF-I levels that were in the normal range over 12 months of treatment. IGF-I is a hormone that works together with growth hormone to make children grow taller. circle Both treatments were just as safe. Most of the side effects children had during treatment were mild or moderate, and none of the children had to stop their treatment because of side effects. A side effect is a medical problem (expected or unexpected) that occurs during the study that may or may not be caused by the treatment being taken. center dot The results from this analysis of 45 Asian children agreed with the results for the whole study group, which had 224 children. center dot Asian children agreed with the results for the whole study group, which had 224 children. Asian children living with GHD may have better growth with weekly somatrogon than with daily somatropin because they may be less likely to miss injections if they only need to inject the treatment once a week instead of every day. The purpose of this plain language summary is to help you to understand the findings from recent research. center dot Somatrogon and somatropin are approved to treat growth hormone deficiency (the condition under study that is discussed in this summary). Approval varies by country; please check with your local healthcare provider for more details. center dot This summary reports the results of a single study. The results of this study may differ from those of other studies. Health professionals should make treatment decisions based on all available evidence and not on the results of a single study.

키워드